Christopher Benecchi - Oct 1, 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Commercial Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
Stock symbol
SAGE
Transactions as of
Oct 1, 2021
Transactions value $
$0
Form type
4
Date filed
10/4/2021, 04:10 PM
Previous filing
Sep 13, 2021
Next filing
Feb 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +45K $0.00 45K Oct 1, 2021 Common Stock 45K $45.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on October 1, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 11,250 shares of common stock shall vest on the one year anniversary of September 13, 2021, with 33,750 shares vesting in 36 equal monthly installments thereafter.